Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: Vendor-neutral scientific reference catalog record for compound identity, classification, structure description, pharmacology, pharmacokinetics, research routes, and study-reference data.
Also known as: 2FA-GLP-1 receptor agonist
This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.
Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.
TE-8105 is a synthetic, dual-fatty-acid-conjugated GLP-1 receptor agonist designed with an Aib-substituted and azido-containing GLP-1 analog coupled by copper-catalyzed azide-alkyne cycloaddition to an alkyne-containing linker bearing one palmitoleic-acid chain and one octadecanedioic-acid chain. The fatty-acid bundle and linker are intended to increase albumin association and prolong systemic exposure. Preclinical studies evaluated TE-8105 in diabetic db/db mice, diet-induced-obese mice, GAN-DIO-NASH mice, and Sprague-Dawley rats. A first-in-human open-label study evaluated single and repeated subcutaneous doses in adults with overweight or obesity without type 2 diabetes mellitus. A separate patent reported sublingual formulations and mouse studies; these findings remain preclinical and do not establish human sublingual efficacy or dosing.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Preclinical subcutaneous dosing included TE-8105 at 1, 3, 10, 30, and 100 nmol/kg in db/db mice; 3–100 nmol/kg every 4 days for 40 days in diet-induced-obese mice; and 5, 10, or 30 nmol/kg once daily for 70 days in GAN-DIO-NASH mice. Chronic db/db mouse studies used 10 or 30 nmol/kg every 2 days for 8 weeks. The first-in-human study used single ascending subcutaneous doses of 0.5, 0.75, 1.5, and 3.0 mg. Multiple-dose cohorts used 1.0 mg every 2 weeks for five doses, or a titration sequence of two doses each at 1.5, 2.0, and 2.5 mg followed by three doses at 3.0 mg every 2 weeks. A patent reported mouse sublingual studies using twice-daily administration, including 200 nmol/kg and selected formulation experiments; these are reported preclinical regimens for reference and are not dosing recommendations. The reviewed evidence describes TE-8105 as an investigational compound in preclinical and early clinical development.
Supplementary research context only. Not medical advice or a treatment recommendation.
Development code: TE-8105; preclinical publication DOI: 10.1021/acs.jmedchem.4c02153; preclinical PMID: 40044142; first-in-human publication DOI: 10.1002/jcph.70224; first-in-human PMID: 42530137
The published preclinical rat pharmacokinetic study reported a terminal half-life of 31.34 hours, a Tmax of 24 hours, and a mean residence time of 53.30 hours after a single dose. The first-in-human study reported an approximate terminal plasma half-life of 120 hours and a median Tmax of 36 hours after a 3.0 mg single subcutaneous dose. The clinical study was open-label and small, and its pharmacodynamic findings were exploratory rather than confirmatory efficacy results.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention TE-8105 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.